SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE as Chairman
SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE as Chairman
Highly experienced biotech veteran to support SENISCA’s rapid development of its senotherapeutic platform
Exeter, UK — 14 November 2023: SENISCA SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and treat age-related disease, today announces the appointment of Dr. David Chiswell Ph.D, OBE as Chairman of the Board.
Dr. David Chiswell is one of the UK’s most successful biotechnology executives, with extensive experience in the development of early-stage biotechnology companies over 30 years in the industry. He joins the SENISCA Board having co-founded Cambridge Antibody Technology (CAT) in 1990 and served as its Chief Executive Officer (‘CEO’) from 1996 to 2002, taking CAT onto both the London Stock Exchange and Nasdaq. He also served as CEO of Nabriva Therapeutics from 2009 to 2012, following which he was appointed as CEO of Kymab Ltd. from 2015 to 2018. Dr. Chiswell currently serves as Chairman of Epsilogen Ltd. and is a director of Avillion Bond 2 Development 2 GP and the Schiehallion Fund (LSE:MNTN).
Dr. Chiswell has served as the Chairman of the Board of various biotechnology companies including Albireo, Arrow and Sosei. He was also formerly Chairman of the UK BioIndustry Association, with his major contributions to the industry being recognized with the awarding of an OBE by HM the Queen in 2006.
Dr. Sarah Cole, CEO of SENISCA, commented: “We are honoured to welcome Dr. Chiswell to our Board at SENISCA. His deep knowledge and expertise in the biotechnology sector – particularly in early-stage companies, combined with his strategic expertise will be crucial as we continue our evolution towards becoming a clinical stage biotechnology company developing novel senotherapeutics to treat age-related disease. Our ability to attract someone of David’s calibre speaks volumes about the quality of our science and the strong foundational work our team has undertaken.”
Dr. David Chiswell, Chairman of the Board of SENISCA commented: “SENISCA is a revolutionary company with the potential to transform the landscape of senotherapeutic treatments. I am thrilled to be joining the Company as Chairman, and I look forward to collaborating with the Board and leadership team as SENISCA progresses into the next stage of its development.”
- Ends -
For more information
Sarah Cole
Chief Executive Officer, SENISCA
info@senisca.com
For media
ICR Consilium
Chris Welsh, Evi Useh
welsh@consilium-comms.com
About SENISCA
SENISCA is an award-winning, RNA therapeutics spinout from the University of Exeter. The Company is focused on modulating RNA biology to treat age-related disease. Underpinned by more than 15 years of world-leading research, SENISCA has identified an officially recognized, novel and druggable component of the cellular ageing (senescence) response, which can be specifically targeted in the context of multiple pharmacological and skin health indications.
The Company is developing a portfolio of proprietary senotherapeutics, that target cell senescence for cellular rejuvenation in the treatment of age-related disease. SENISCA’s senotherapeutics specifically target the novel cellular pathway which causes cell rejuvenation and positively impacts markers of disease modification in patient-derived models. In line with the rapid evolution of the company, R & D activities are focused on IND data generation.
SENISCA’s platform technology has broad applicability for multiple age-related diseases including those of the eyes, lungs, joints, and brain. For many such diseases, current treatments are palliative rather than curative, with varying success rates. These diseases represent a high unmet medical need, are amenable to a local route of therapeutic administration and are driven by senescence. Targeting these specific diseases will streamline progress towards the clinic by avoiding potential pitfalls of systemic delivery.
SENISCA’s novel senotherapeutics will be mined and commercialized through partnership or co-development models that will sit alongside internal programmes. If you would like to learn more about SENISCA, please contact Jennie Jepperson, Executive Assistant at SENISCA (Jennie.Jepperson@senisca.com).
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nykredit Realkredit A/S – New final terms for Euro Medium Term Note Programme5.12.2023 08:32:38 CET | Press release
To Nasdaq Copenhagen Nykredit Realkredit A/S – New final terms for Euro Medium Term Note Programme Nykredit Realkredit A/S publishes final terms for an issue of SEK 500,000,000 Senior Non-Preferred Floating Rate Notes due 2027, which are issued pursuant to Nykredit Realkredit A/S's and Nykredit Bank A/S’s €15,000,000,000 Euro Medium Term Note Programme dated 12 May 2023. The final terms dated 1 December 2023 and the EMTN Programme dated 12 May 2023 are available for download on Nykredit's website at nykredit.com/ir. Enquiries may be addressed to Nykredit Realkredit A/S, Group Treasury, Nicolaj Legind Jensen, Head of Group Treasury, tel +45 44 55 11 10, or Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21. Attachment New_final_terms_for_Euro_Medium_Term_Note_Programme_Nykredit_Realkredit_A_S_2023-12-05_EN
Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities5.12.2023 08:30:00 CET | Press release
SIENA, Italy, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Philogen S.p.A. (BIT:PHIL) is pleased to announce that its new GMP facility located in Rosia Siena, is now GMP certified. The certification was granted by the GMP MED office of the Agenzia Italiana del Farmaco (AIFA) following an inspection occurred in July 2023. AIFA confirmed that Philogen new facility complies with the requirements and guidelines of Good Manufacturing Practice outlined in the Directive 2003/94/EC issued by the European Parliament. In the European Union, national competent authorities - AIFA in Italy - are responsible for inspecting manufacturing sites based within their own territories. Sites located in one European Member State also benefit from mutual recognition agreements (MRAs) that the European Commission has signed with the authorities of the United States, Switzerland, Canada, Israel, Australia, Japan and New Zealand concerning the conformity assessment of medicinal products. Philogen plant in Rosia was designe
Equinor ASA: Share buy-back5.12.2023 08:00:00 CET | Press release
Please see below information about transactions made under the fourth tranche of the 2023 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR). Date on which the fourth tranche of the 2023 programme was announced: 27 October 2023. The duration of the fourth tranche of the 2023 programme: 30 October 2023 to no later than 29 January 2024. From 27 November to 1 December 2023, Equinor ASA has purchased a total of 1,478,000 own shares at the Oslo Stock Exchange at an average price of NOK 347.8907 per share. Aggregated overview of transactions per day: DateAggregated volume (number of shares)Weighted average share price (NOK)Total transaction value (NOK)27 November298,000351.8852104,861,789.6028 November290,000351.1603101,836,487.0029 November302,000345.0671104,210,264.2030 November296,000348.2593103,084,752.801 December292,000343.1135100,189,142.00Previously disclosed buy-backs under the fourth tranche of the 2023 programme 5,609,000360.82142,023,847,117.50Total buy-backs under fo
AS Tallink Grupp Statistics for November 20235.12.2023 08:00:00 CET | Press release
In November 2023 AS Tallink Grupp transported 376,997 passengers, which is a 0.4% decrease compared to November 2022. The number of cargo units decreased by 20.8% to 26,547 units and the number of passenger vehicles decreased by 4.6% to 50,244 units in the same comparison. AS Tallink Grupp passenger, cargo unit and passenger vehicles numbers for November 2023 were the following: November 2023November 2022ChangePassengers376,997378,540-0.4%Finland-Sweden116,913131,606-11.2%Estonia-Finland225,068207,0718.7%Estonia-Sweden35,01639,863-12.2%Cargo Units26,54733,502-20.8%Finland-Sweden3,4184,066-15.9%Estonia-Finland19,03624,999-23.9%Estonia-Sweden4,0934,437-7.8%Passenger Vehicles50,24452,688-4.6%Finland-Sweden2,8403,804-25.3%Estonia-Finland46,22947,555-2.8%Estonia-Sweden1,1751,329-11.6% FINLAND–SWEDEN In November 2023, the Finland-Sweden results reflect the operation of the two cruise ferries on the Helsinki-Stockholm and one cruise ferry on the Turku-Kapellskär route. The cruise ferry Silja
Progress on share buyback programme5.12.2023 08:00:00 CET | Press release
Progress on share buyback programme ING announced today that, as part of our €2.5 billion share buyback programme announced on 2 November 2023, the company repurchased 22,777,914 shares during the week of 27 November 2023 up to and including 1 December 2023. The shares were repurchased at an average price of €12.78 for a total amount of €291,049,616.02. For detailed information on the daily repurchased shares, individual share purchase transactions and weekly reports, see the ING website at www.ing.com/investorrelations. In line with the purpose of the programme to reduce the share capital of ING, the total number of shares repurchased under this programme to date is 93,562,112 ordinary shares at an average price of €12.53 for a total consideration of €1,172,310,567.38. To date approximately 46.89% of the maximum total value of the share buyback programme has been completed. Note for editors For further information on ING, please visit www.ing.com. Frequent news updates can be found in